Industry research
Dermatology Services
Scope
US
Companies
91
Key takeaways
What is the scope of this industry report?
The US dermatology services market spans the diagnosis and treatment of conditions affecting the skin, hair and nails, along with laboratory-based diagnostic testing and the non-clinical infrastructure that supports dermatology practices. Within this context, identified players deliver care through outpatient clinics and virtual consultations, provide specialist pathology services for tissue-based diagnosis or support affiliated practices through centralized functions such as billing, payer contracting, recruiting, IT, marketing and acquisition integration.Accordingly, we segmented the market by service offering into:
clinical dermatology,
dermatopathology,
practice management platforms
What does the Dermatology services landscape look like in the US?
The US dermatology services landscape remains fragmented across all segments, with independent practices and physician-led laboratories operating alongside a limited number of scaled clinical networks and practice management platforms. Within clinical dermatology, scaled groups (e.g. Forefront Dermatology) operate across multi-state networks, while independent practices remained predominant by practice count, accounting for ~82% of US dermatology practices in 2022. Dermatopathology similarly comprises a long tail of smaller laboratories competing with larger diagnostic networks, in-house laboratories within clinical groups and academic or hospital-based providers. Practice management platforms expand through acquisitions and affiliations, centralize non-clinical functions and offer physicians varying ownership and profit-sharing arrangements. Across the landscape, technology supports virtual consultations, automated laboratory workflows, specimen tracking, electronic reporting, digital slide review and AI-enabled clinical and administrative processes. Overall, consolidation is most evident in clinical dermatology and practice management platforms, where acquisitions and affiliations are used to broaden geographic coverage and expand practice networks.
What does the cold chain logistics market landscape look like in the US?
Investor-led interest remains limited, with ~22% of identified assets being sponsor-backed (August 2026). Investment appeal is supported by:
Rising skin cancer incidence and population aging
Adoption of AI-enabled clinical and administrative tools that improve practice productivity, clinical capacity and margin resilience, and
Therapeutic innovation across chronic inflammatory skin conditions that broadens treatment options and supports recurring care demand.
Deterring factors for investment include
Medicare reimbursement pressure that could compress practice margins and limit resources for staffing and capacity expansion,
Persistent dermatologist shortages and uneven geographic distribution that constrain appointment availability and clinic expansion,
Heightened state oversight of private investment that increases execution risk and could slow platform acquisitions and affiliations.
What are the key ESG considerations in the US's Dermatology Services industry?
ESG topics relate to environmental, social and governance issues. Environmental concerns center on clinical and laboratory waste from disposable supplies, sharps, specimen containers and chemical reagents, compounded by incorrect segregation that can send ordinary materials into regulated medical waste streams. To reduce operational waste, identified players conduct waste audits, train staff on proper segregation, use clearly labeled bins, streamline procedure kits and reuse or recycle clinical and laboratory materials where appropriate. Social concerns center on limited access to dermatologic care in rural and underserved communities due to limited specialist availability, longer travel distances and appointment waits. To improve access, identified players establish clinics in rural markets and use teledermatology, mobile or on-site care, community screening partnerships and team-based staffing models. Governance concerns relate to non-physician influence over physician-owned practices, risks to clinical autonomy, patient data privacy and cybersecurity. To manage these risks, identified players preserve physician control over clinical decisions and strengthen data security through multifactor authentication, encryption, access controls, staff training and incident response planning.
Company benchmarking
Market growth
Technavio (March 2026) estimates that the global dermatology market reached ~$25.9bn in revenue in 2025, a figure expected to grow to ~$49.9bn by 2030 (+14.0% CAGR 2025-2030)
US melanoma incidence is projected to rise from ~101k cases in 2020 to ~219k by 2040 (+3.9% CAGR 2020-2040; JAMA Network Open, April 2021)
Positive drivers
Rising skin cancer incidence will continue to drive demand for examinations, biopsies, excisions, Mohs surgery and dermatopathology, leading to higher visit, procedure and specimen volumes. For instance, population aging will reinforce this demand, with melanoma incidence rates among adults aged ≥50 increasing by ~2.8% annually in women and ~1.4% in men (Melanoma Research Alliance, January 2026; JAMA Network Open, April 2021)
AI-enabled clinical and administrative tools (e.g. clinical image assessment, AI-assisted dermatopathology analysis, automated clinical documentation and prior authorization) will support broader digital adoption across US dermatology practices, improving practice productivity and supporting greater clinical capacity and margin resilience. To illustrate, a March 2026 survey stated that ~88% of practice owners used AI to improve efficiency (Clarity RCM, June 2026; Dermatology Times, June 2026)
Therapeutic innovation broadens treatment options across chronic inflammatory skin conditions and supports recurring dermatology demand. For example, recent FDA approvals include Anzupgo for moderate-to-severe chronic hand eczema (July 2025) and Adquey for mild-to-moderate atopic dermatitis (February 2026), alongside continued advances in plaque psoriasis therapies (FDA, August 2026; FDA, July 2026)
Negative drivers
Medicare reimbursement pressure may weigh on dermatology practice economics, as lower payments for office-based care would compress margins and limit resources for staffing and capacity expansion. To illustrate, the proposed 2027 Physician Fee Schedule could reduce aggregate Medicare payments to dermatologists by ~9%, driven in part by revised practice expense calculations and lower reimbursement for certain services performed on the same day (AAD, August 2026; CMS, July 2026).
Persistent dermatologist shortages are expected to constrain appointment capacity and practice expansion across US markets, with uneven geographic distribution intensifying capacity gaps in areas with fewer specialists. As a result, competition for available dermatologists may lengthen hiring cycles and raise compensation requirements, slowing clinic ramp-up and limiting providers’ ability to convert underlying demand into additional patient volumes (AAD, August 2026; JDD, May 2025)
Heightened state oversight of private investment in healthcare could slow consolidation in US dermatology, as expanded transaction review and restrictions on clinical control add execution risk to platform acquisitions and affiliations. For instance, 13 states have enacted transaction notice and review statutes, while additional 2026 proposals (e.g. Rhode Island’s H7720 and H7721) could widen filing duties and tighten corporate-practice restrictions, lengthening deal timelines and narrowing acquisition appetite (Norton Rose Fulbright, August 2026; Reuters, December 2025)
Fill out the form to request your copy of the Dermatology Services industry report
With the full report, you’ll gain access to:
Detailed assessments of the market outlook
Insights from c-suite industry executives
A clear overview of all active investors in the industry
An in-depth look into 91 private companies, incl. financials, ownership details and more.
A view on all 169 deals in the industry
ESG assessments with highlighted ESG outperformers
Discover hundreds of niche industry reports on Gain
Deep dive into additional industries to understand their market outlook, positive and negative drivers, and more!
